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Abstract 
Targeted radionuclide therapy, which is based on the selective delivery of a sufficient radiation 
dose to tumors without significantly affecting normal tissues, is a promising therapeutic ap-
proach for the treatment of a wide variety of malignancies. Integrins, a family of cell adhesion 
molecules, play key roles during tumor angiogenesis and metastasis. Among all the integrins, 
αvβ3 seems to be the most important in the process of tumor angiogenesis. Integrin αvβ3 is 
highly expressed on activated endothelial cells, new-born vessels as well as some tumor cells, 
but is not present in resting endothelial cells and most normal organ systems, making it a 
suitable target for anti-tumor therapy. In this review, we summarize the current development 
and applications of antibody-, peptide-, and other ligand-based integrin targeted radiothera-
peutics for tumor radiation therapy. 
Key words: Cancer, integrin, radionuclide, radioimmunotherapy (RIT), peptide receptor radionu-
clide therapy (PRRT) 
Introduction 
Tumor angiogenesis, the sprouting of new blood 
vessels  from  preexisting  vasculature,  is  well  recog-
nized  as  an  essential  mechanism  for  tumor  growth 
and  development  of  metastasis  [1,  2].  Without  the 
formation of neovasculature to provide oxygen and 
nutrients, tumors cannot grow beyond about 1~2 mm 
in size [3, 4]. Once vascularized, previously dormant 
tumors  begin  to  grow  rapidly,  invade  surrounding 
tissues (invasion), and transfer to distant sites in the 
body (metastasis). The angiogenic process depends on 
vascular endothelial cell migration and invasion, and 
is regulated by cell adhesion receptors. Integrins rep-
resent a subclass of cell adhesion molecules connect-
ing  the  cytoskeleton  with  the  extracellular  matrix 
(ECM) or other cells. Integrins consist of two genet-
ically nonrelated subunits, α and β, which are non-
covalently associated with each other. In mammals, 
there are 18 α and 8 β subunits capable of assembling 
at  least  24  different  functional  heterodimers  [5-7]. 
Members of the integrin family play vital roles in the 
regulation of cellular activation, migration, prolifera-
tion, survival, and differentiation [8, 9]. Among all of 
the integrins, integrin αvβ3 has been identified as the 
most important member with overexpression pattern 
among vascular cells during tumor angiogenesis and 
vascular  remodeling  [1,  10,  11].  Integrin  αvβ3  is 
highly  expressed  on  activated  endothelial  cells  and 
new-born vessels, but is absent in resting endothelial Theranostics 2011, 1 
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cells  and  most  normal  organ  systems,  making  it  a 
suitable target for anti-angiogenic cancer therapy. In 
addition,  it  is  also  expressed  on  some  tumor  cells, 
allowing for both tumor cell and tumor vasculature 
targeted therapy. To date, numerous anti-angiogenic 
therapies  based  on  integrin  αvβ3  antagonism,  in-
cluding antibodies, peptides, small molecules, small 
interfering RNA (siRNA) have been investigated [12].  
Targeted  delivery  of  radionuclides  by  tu-
mor-specific  ligands  (antibodies,  peptides,  or  small 
proteins) can specifically deliver radiation to tumors, 
while sparing the normal organs and tissues. The ra-
diation energy given off by the radionuclides would 
also kill the adjacent tumor cells, which do not express 
the  target  antigen  (so-called  “crossfire”).  In  recent 
years, tumor targeted radionuclide therapy restimu-
lates  the  interests  of  physicians  especially  after  the 
successful clinical applications of the two Food and 
Drug  Administration  (FDA)  approved  antibodies 
(Zevalin and Bexxar) for radioimmunotherapy (RIT) 
of  non-Hodgkin’s  lymphoma  (NHL)  [13].  Although 
RIT of solid tumors has shown less progress, a series 
of novel tumor targeted radiotherapeutic agents with 
favorable  in  vivo  pharmacokinetics  and  enhanced 
tumor-to-nontumor ratios have been investigated in 
preclinical  studies,  and  some  of  them  are  tested  in 
clinical trials. In this article, we will first introduce the 
radionuclides and bifunctional chelators that are be-
ing used for tumor targeted radionuclide therapy, and 
then  summarize  the  current  development  of  integ-
rin-targeted radiotherapeutics.  
Radionuclides and bifunctional chelators 
A tumor targeted radionuclide therapeutic agent 
is  typically  composed  of  the  radionuclide  and  the 
targeting ligand (antibodies, peptides, or small pro-
teins). For direct radio-iodination (with 131I, 125I or 123I), 
the  iodine-ligand  complex  can  be  easily  prepared. 
However, almost all metal radionuclides require che-
lation chemistry for attachment to the ligand. Bifunc-
tional chelators (BFCs) that possess specific functional 
groups allow both conjugation to ligands and stable 
complex formation with metal radionuclides. 
Therapeutic radionuclides  
The  suitability  of  a  radionuclide  for  radiation 
therapy depends on its physical and chemical prop-
erties and the nature of the radiation, such as low or 
high linear energy transfer (LET) emission. The most 
commonly  used  radionuclides  in  tumor  targeted 
therapy  are  β-emitters,  although  Auger  elec-
tron-emitting  radionuclides  and  α-emitters  are  also 
being used (Table 1) [14]. 
 
Table 1. Selected radionuclides useful for tumor targeted radiotherapy 
Nuclide  Emission  Half-life  Emax (MeV)  Mean 
range (mm) 
Source  Imageable 
90Y  β  2.7 d  2.30  2.76  generator  No 
131I  β, γ  8.0 d  0.81  0.4  reactor  Yes 
177Lu  β, γ  6.7 d  0.50  0.28  reactor  Yes 
186Re  β, γ  3.8 d  1.1  0.92  accelerator or reactor  Yes 
188Re  β, γ  17.0 h  2.1  2.43  generator  Yes 
67Cu  β, γ  2.6 d  0.57  0.6  accelerator  Yes 
213Bi  α  45.7 min  5.87  0.04-0.1  generator  Yes 
212Bi  α  1.0 h  6.09  0.04-0.1  generator  Yes 
211At  α  7.2 h  5.87  0.04-0.1  accelerator  Yes 
67Ga  Auger, β, γ  3.3 d  0.18  0.001-0.02  accelerator  Yes 
111In  Auger, γ  2.83 d  0.86  0.001-0.02  accelerator  Yes 
 
 
131I and 90Y are the two most widely used radi-
onuclides  in  clinical  practice  today.  131I  is  readily 
available,  inexpensive,  and  can  also  provide 
γ-imaging  emissions,  which  makes  it  possible  for 
monitoring the therapeutic efficacy during the period 
of  radiation  therapy.  However,  the  conventional 
conjugation of 131I to antibodies results in rapid deg-
radation and a reduced residence time in the tumor, 
thus diminishing the tumor dose [15].  90Y is a more 
energetic  pure  β-emitter  and  thus  has  fewer  envi-
ronmental radiation restrictions. 90Y possesses greater 
emission range and most of the decay energy is de-
posited in tumors only  if their diameter is 1 cm or 
more [13], which makes 90Y more suitable for irradia-
tion  of larger tumors. Since  90Y is a pure β-emitter, 
111In is usually chosen as the surrogate for imaging 
and dosimetry determination. 177Lu is an isotope with 
lower  energy  and  longer  half-life  compared  to  90Y. 
177Lu has an imageable γ emission and this property 
also  allows  tracking  the  radiolabeled  agents  during Theranostics 2011, 1 
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therapy  procedures  by  using  external  gamma  scin-
tigraphy. Rhenium isotopes (186Re and 188Re) have also 
been used for RIT, and have sufficient γ-energies for 
external scintigraphy, similar to 131I. 67Cu remains an 
interesting  candidate  for  therapy  with  regards  to 
emission  energy,  half-life  and  imageable  emissions. 
Based on the good results of preclinical and clinical 
evaluations of  67Cu-labeled antibodies, broader clini-
cal  investigations  in  radioimmunotherapy  trials  are 
desirable.  However,  the  availability  of  the  67Cu  nu-
clide is a limiting factor for its more widespread use. 
Efforts  to  develop  efficient  procedures  to  produce 
large  amounts  of  67Cu  with  high  specific  activity 
would be much more helpful [16]. 
Radiation therapy with α-emitters has received 
renewed  interest  recently,  especially  with  bismuth 
nuclides, such as 212Bi and 213Bi as eluates from 234Ra 
and  225Ac  generators,  respectively  [17].  The  cyclo-
tron-produced radiohalogen 211At is also a promising 
candidate for RIT applications on the basis of half-life 
(t1/2 =7.2 h). The α-particle RIT is best used when there 
are  micrometastases  or  circulating  tumor  cells,  not 
bulky  disease,  because  of  their  high  LET  and  short 
effective path length in tissues  [18]. Such high LET 
radiation  has  profound  effects  on  DNA,  causing 
strand  breaks.  Low-energy  Auger  electron-emitters 
are also used as alternative to α- or β-emitters for RIT. 
Most Auger electrons travel nanometer to micrometer 
distances  in  tissue  and  have  high  LET  values  ap-
proaching  those  of  α-emitters  (4-26  keV/μm)  [19]. 
These  properties  render  Auger  electron-emitters 
highly  cytotoxic  and  damaging  to  DNA  when  they 
decay intracellularly, especially when they decay in 
close proximity to the cell nucleus [20]. Studies have 
demonstrated that Auger emitters, such as  67Ga and 
111In,  might  have  a  significant  role  as  therapeutics, 
even if their clinical use might be limited to irradia-
tion of microscopic residual disease [21].  
Bifunctional Chelators 
Radiolabeling with the radiometals is performed 
by means of chelation with chelators (Figure 1). Ra-
dioiodinated  tyrosine  is  considered  to  be  excreted 
from the cell after internalization, where the chelated 
radiometals  (such  as  90Y  or  177Lu)  metabolites  are 
trapped in the lysosomes, thereby increasing the re-
tention  time  of  the  isotope  within  the  tumor  [13]. 
DTPA (diethylene triamine pentaacetic acid) can che-
late 111In, and 111In-DTPA-Octreotide (OctreoScan) is a 
commonly  used  agent  in  clinical  application  [22]. 
DTPA  and  derivatives  usually  lead  to  fast  reaction 
kinetics [23]. DOTA (1,4,7,10-tetraazacyclododecane- 
1, 4, 7,10-tetraacetic acid) is a bifunctional chelator for 
the complexation of various diagnostic radioisotopes, 
such as 64Cu, 68Ga, 86Y and 111In, but also for the com-
plexation of therapeutic radioisotopes, such as  67Cu, 
177Lu and  90Y  [24, 25]. DOTA is able to form  stable 
complexes with divalent and trivalent metals. NOTA 
(1,4,7-triazacyclononane-1,4,7-triacetic  acid)  and 
TETA  (1,4,8,11-tetraazacyclododenane-1,4,8,11- 
tetraacetic  acid)  are  macrocyclic  pyazapolycarbox-
ylate chelators, which are characterized by a higher 
stability than DOTA for 64Cu labeling in vivo [26, 27].  
 
Figure 1. Chemical structures of some common bifunc-
tional  chelators.  DOTA  =  1,4,7,10-tetraazacyclodode-
cane-1,  4,  7,10-tetraacetic  acid;  NOTA  = 
1,4,7-triazacyclononane-1,4,7-triacetic  acid;  DTPA  =  di-
ethylene  triamine  pentaacetic  acid;  TETA  = 
1,4,8,11-tetraazacyclododenane-1,4,8,11-tetraacetic acid.  
 
Integrin αvβ3 targeted radionuclide therapy   
The crucial roles of integrin αvβ3 in tumor an-
giogenesis have led to a promising strategy to block 
its  signaling  by  antagonists,  as  this  would  theoreti-
cally inhibit the tumor angiogenesis or enhance the 
efficacy of other tumor therapeutics. In addition, the 
high expression of integrin αvβ3 on tumor new-blood 
vessels and some tumor cells makes the integrin αvβ3 
a suitable maker for cancer-targeted drug delivery [5, 
12]. Several delivery vehicles such as antibodies, RGD 
peptides, peptidomimetics, and other small molecules 
have been investigated for integrin targeted delivery 
of chemical drugs, cytotoxicities and gene inhibitors 
[12]. Integrin αvβ3 targeted radionuclide therapy of Theranostics 2011, 1 
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tumors by use of antibodies and RGD peptides was 
also investigated in the last decades. 
Antibody-based radiotherapeutics targeting in-
tegrin αvβ3 
The  targeted  systemic  delivery  of  radiation  to 
tumors  through  radiolabeled  antibodies  (radioim-
munotherapy)  offers  several  potential  advantages 
over external beam radiotherapy, including the ability 
to specifically target multiple sites of disease, avoid or 
minimize normal tissue toxicity, and cause cell death 
of adjacent tumor cells. Preclinical and clinical inves-
tigations  with  murine  mAbs  highlighted  several  is-
sues that require attention before successful applica-
tions in cancer management. Foremost of these issues 
was the inevitable production of human antimurine 
immunoglobulin  antibodies  (HAMA)  after  one  to 
three treatments in patients. Some other factors lim-
iting treatment include inadequate therapeutic dose 
delivered to tumor lesions, slow blood clearance, high 
uptake in normal organs, and insufficient tumor pen-
etration. To date, this efforts such as the production of 
chimeric  mAbs,  grafting  of  complementari-
ty-determining region (CDR) or complete humaniza-
tion  of  the  protein  have  primarily  been  applied  to 
eliminate HAMA [28].   
Recently, we prepared a 90Y-labeled humanized 
anti-integrin  αvβ3  monoclonal  antibody  AbegrinTM 
and evaluated the RIT efficacy in U87MG glioblasto-
ma xenograft models [29]. Maximum tolerated dose 
(MTD) and dose response analysis revealed 200 μCi 
per mouse as appropriate treatment dose with hepatic 
clearance  and  no  organ  toxicity  (Figure  2). 
90Y-Abegrin showed partial tumor regression with a 
final fractional tumor volume (Vfinal/Vinitial) of 0.69, as 
compared with that of 3.76 for 90Y-hIgG and 5.43 for 
normal  AbegrinTM  controls,  respectively  (Figure  3). 
[18F]-fluorodeoxyglucose  (18F-FDG)  microPET  imag-
ing  revealed  a  reduction  of  cell  proliferation  and 
metabolic  activity  whereas  3’-[18F]fluoro-3’- 
deoxythymidine  (18F-FLT)  reflected  decreased  DNA 
synthesis in the  90Y-AbegrinTM group (Figure 4A-D). 
Ex vivo histological analysis also confirmed the ther-
apeutic  efficacy  of  90Y-AbegrinTM.  It  was  concluded 
that radioimmunotherapy with 90Y-labeled AbegrinTM 
may prove promising in the treatment of highly vas-
cular,  invasive,  and  heterogeneous  malignant  brain 
tumors [29].  
 
 
Figure 2. A maximum tolerated dose (MTD) study was completed using escalating 
90Y-Abegrin
TM of 50,100,150, 200, and 
300 μCi. Each dose was tested in seven female athymic nude mice. (A) Body weight changes of animals. (B-E) Animals that 
received 300 μCi suffered from hematologic toxicity with a decline in WBC (B), RBC (C), HGC (D), and platelet counts (E), 
and eventual mortality. Animals that received 50, 100, 150, or 200 μCi of activity did not experience significant reductions 
in WBC, RBC, HGC, or platelet counts. Adapted with permission from [29]. Theranostics 2011, 1 
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Figure 3. 
90Y-Abegrin
TM dose response and inhi-
bition of human glioblastoma growth in vivo. Nude 
mice bearing U87MG tumors were injected with a 
one-time  dose  of  100  μCi  of 
90Y-Abegrin
TM, 
90Y-IgG, Abegrin
TM, or saline. The growth inhibition 
of experimental groups was monitored via serial 
caliper  measurements. 
90Y-Abegrin  treatment 
animals maintained a statistically significant reduc-
tion in tumor size beginning on posttreatment day 
2 and eventually showed partial tumor regression 
whereas all other groups showed increased final 
fractional tumor volumes. Adapted with permis-
sion from [29]. 
 
 
 
 
Figure 4. (A-B) Representative coronal microPET images and radioactivity accumulation quantification of female athymic 
nude mice bearing U87MG tumors (treated with 
90Y-Abegrin
TM, 
90Y-IgG, Abegrin
TM, or saline) after i.v. injection of 
18F-FDG 
(A) and 
18F-FLT (B). (C) 
18F-FDG imaging revealed a statistically significant reduction in both 
90Y-Abegrin
TM and Abegrin
TM 
signal intensity, suggesting reduced metabolic activity. (D) 
18F-FLT imaging showed reduced tumor accumulation value in 
90Y-Abegrin
TM group, reflecting reduced DNA synthesis. Adapted with permission from [29]. Theranostics 2011, 1 
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The strategy to overcome the problems of intact 
antibodies, such as slow blood clearance, high back-
ground  uptake,  insufficient  tumor  penetration,  has 
been the development of small molecular constructs, 
such as antibody fragments (e.g., Fab’ and F(ab’)2) and 
subfragments (e.g., scFv, (sFv)2), which are capable of 
binding to the tumor while clearing from normal tis-
sues rapidly [28]. However, the tumor residence time, 
which is important for delivering therapeutic radia-
tion doses, also significantly decreases as the immu-
noglobulin  fragment  becomes  smaller.  The  pretar-
geting strategies that separate tumor targeting from 
delivery of the therapeutic radionuclide are also being 
considered to design optimized RIT agents. However, 
up to now, there are not extensive investigations of 
integrin targeted cancer radioimmunotherapy by use 
of such antibody fragments or pretargeting delivery 
systems. 
RGD peptide-based radiotherapeutics targeting 
integrin αvβ3 
Peptides are usually classified as containing less 
than 50 amino acids, ~5500 Da. This low molecular 
weight  renders  peptides  low  in  antigenicity,  fast  in 
clearance, and rapid in tissue and tumor penetration. 
In  contrast  to  monoclonal  antibodies,  automated 
techniques allow peptides to be produced easily and 
inexpensively [30]. In recent years, a wide variety of 
peptides have been identified with high affinity for 
characteristic  receptors  that  are  overexpressed  on  a 
large number of tumor cell types.  
Since integrin αvβ3 binds a wide range of ECM 
molecules (such as fibronectin, fibrinogen, von Wil-
lebrand factor, vitronectin, and proteolysed forms of 
collagen  and  laminin)  with  an  Arg-Gly-Asp  (RGD) 
triplepeptide motif [29, 31], RGD peptides and ana-
logues  were  therefore  chemically  synthesized  to 
mimic the structure of the natural ligands of integrins 
and used as the integrin αvβ3 targeting vehicles. The 
RGD triple-peptide itself is limited in the in vivo use 
because  of  its  short  circulation  half-life.  Conforma-
tional restriction by ring closure of the peptides and 
further  chemical  modification,  such  as  the  use  of 
D-amino acids, like in the c(RGDfV) (with f standing 
for D-phenylalanine) compound, not only increased 
their αvβ3 binding affinity, but also improved their 
bioavailability [32]. In the last decades, a series of ra-
diolabeled cyclic RGD peptides and analogues have 
been  intensively  investigated  for  positron  emission 
tomography (PET) and single photon emission com-
puted tomography (SPECT) imaging of integrin αvβ3 
expression [5, 33, 34]. However, only a small fraction 
of reports cover therapeutic tumor targeting. Janssen 
et al. [35] studied the  in vivo behavior  of the radio-
labeled dimeric RGD peptide E[c(RGDfK)]2 in a sub-
cutaneous (s.c.) ovarian carcinoma nude mouse mod-
el.  The  dimeric  peptide  E-[c(RGDfK)]2  labeled  with 
111In, 90Y and 99mTc, respectively. Tumor uptake was as 
high  as  7.5  %ID/g  (111In-DOTA-[c(RGDfK)]2)  at  2  h 
p.i. or 6.0 %ID/g (99mTc-HYNIC-E-[c(RGDfK)]2) at 1 h 
p.i.  A  single  injection  of  37  MBq  of 
90Y-DOTA-E[c(RGDfK)]2  in  mice  with  small  s.c.  tu-
mors caused a significant growth delay as compared 
with  control  mice.  Treatment  with  37  MBq  of 
90Y-DOTA-E[c(RGDfK)]2 caused significant increased 
survivals as compared to mice treated with 37 MBq 
90Y-labeled control peptide or untreated mice (median 
survival of 54 versus 33.5 versus 19 days, respective-
ly).  Unfortunately,  in  a  follow-up  study,  increasing 
the number of injections did not improve the thera-
peutic  efficacy  [36].  Moreover,  the  prominent  renal 
uptake of this conjugate limited its potential in clinical 
applications.   
It has been proposed by others and us that the 
receptor binding characteristics of dimeric and mul-
timeric  RGD  peptides  would  be  better  than  that  of 
monomeric RGD peptide based upon polyvalency [24, 
33, 35, 37, 38]. The receptor binding of the one RGD 
peptide  will  significantly  enhance  the  local  concen-
tration of the other RGD peptide in the vicinity of the 
receptor, which may lead to a faster rate of receptor 
binding or a slower rate dissociation of the dimeric 
RGD probes. The dimeric or multimer RGD peptide 
with almost one order of magnitude higher integrin 
binding affinity than the monomeric analog, and thus 
the dimeric or multimer RGD probes gave the highest 
tumor specific activity accumulation at all time points 
examined as compared to monomeric RGD peptide 
probes. Multimeric RGD  peptides with even higher 
receptor  affinity  and  longer  tumor  retention  time 
might  be  more  suitable  for  clinical  translation.  We 
therefore  used  90Y-labeled  tetrameric  RGD  peptides 
for  integrin  αvβ3-targeted  internal  radiotherapy  of 
athymic nude mice tumor xenografts.  90Y-labeled te-
trameric RGD were more effective in inhibiting integ-
rin-positive  tumor  growth  than  90Y-labeled  dimeric 
RGD, due to the significantly increased tumor uptake 
[39].  However,  the  whole  body  toxicity  of  90Y-RGD 
tetramer was also significantly higher than that of the 
same  dose  of  90Y-RGD  dimer  because  90Y-RGD  te-
tramer also exhibited high uptake in normal organs 
especially the kidneys [39] .  
We  and  our  collaborators  have  recently  devel-
oped a series of new RGD dimers with PEG4 and Gly3 
linkers  [40-45].  The  insertion  of  the  Gly3  or  PEG4 
spacers significantly increased the distance between Theranostics 2011, 1 
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the  two  cyclic  RGD  peptide  motifs,  resulting  in  an 
increase in vitro receptor-binding affinity. Important-
ly,  the  radiolabeled  new  types  of  RGD  dimers  (i.g. 
3PRGD2)  possessed  as  high  tumor  uptake  as  RGD 
tetramer  (RGD4),  but  the  uptake  in  normal  organs 
was much lower compared with RGD tetramer due to 
the improved in vivo kinetics [39-41], which led to a 
lower toxicity and much higher maximum tolerated 
dose (MTD) of 90Y-DOTA-3PRGD2 in mice [39]. Sig-
nificant anti-tumor vasculature effects can be found in 
the  90Y-DOTA-3PRGD2 treatment  group.  Compared 
to  90Y-DOTA-RGD4,  the  low  accumulation  of 
90Y-DOTA-3PRGD2 in normal organs makes it more 
suitable for high dose or multiple-dose regimens, in 
order  to  achieve  maximum  therapeutic  efficacy  for 
integrin αvβ3-positive tumors [39]. 
In  another  report,  considering  that  monomeric 
RGD peptides have a lower molecular mass compared 
with  antibody  or  multimeric  RGD  peptides,  Yo-
shimoto  et  al.  [46]  proposed  that  90Y-labeled  RGD 
monomer  would  be  a  promising  radiopharmaceuti-
cals for tumor therapy causing low radioactive expo-
sure to normal tissues such as kidney and liver. The 
tumor  therapeutic  and  imaging  potential  of 
90Y/111In-labeled monomeric RGD peptide was inves-
tigated in a human ovarian carcinoma mouse model, 
and  it  was  claimed  that  the  RGD  monomer  can  be 
used for fractionated therapy without evident toxici-
ty.  The  radionuclide  therapy  results  demonstrated 
that  multiple  dose  administration  of 
90Y-DOTA-c(RGDfK)  (3  ×  11.1  MBq)  led  to  an  in-
creased tumor growth inhibition in comparison to the 
single-dose administration (11.1 MBq). However, due 
to the lower tumor uptake of the RGD monomer, the 
single-dose  administration  did  not  show  significant 
inhibition  to  tumor  growth  and  the  radionuclide 
therapeutic efficacy of the multiple dose administra-
tion  was  also  generally  limited,  and  the  optimized 
regimens  should  be  considered  to  reach  the  better 
results. 
Others  
Integrin targeted delivery of internal radiother-
apy  by  non-peptide  antagonists  has  also  been  re-
ported.  90Y  and  177Lu  labeled  TA138,  a 
DOTA-conjugated non-peptide integrin αvβ3 antag-
onist,  were  prepared  under  anaerobic  conditions  to 
protect them from radiolytic degradation [47]. These 
complexes were synthesized in high yield and specific 
activity and showed high affinity for integrin αvβ3. 
111In-TA138 was also synthesized for tumor imaging 
purposes as well as for dosimetry determination  of 
90Y-TA138 [48, 49]. High tumor uptake and low back-
ground  activity  of  111In-TA138  were  found  in  the 
c-neu oncomouse mammary adenocarcinoma model 
(9.39 % ID/g at 2 h p.i.). Despite the differences in 
lipophilicity  and  solution  structure  between 
90Y-TA138  and  111In-TA138,  biodistribution  studies 
showed that  111In-TA138 and  90Y-TA138 are biologi-
cally equivalent with respect to the uptakes in tumors 
and  other  major  organs,  indicating  that  111In-TA138 
was useful as an imaging surrogate for 90Y-TA138 and 
could predict the radiation dosimetry of  90Y-TA138. 
Radiotherapy  using  90Y-TA138  in  the  c-neu  on-
comouse  model  demonstrated  a  slowing  of  tumor 
growth at a dose of 15 mCi/m2, and a regression of 
tumors at a dose of 90 mCi/m2 [48].  
Knottin peptides are small constrained polypep-
tides that share a common disulfide-bonded frame-
work and a triple-stranded β-sheet fold [50]. Knottin 
family members possess one or more surface-exposed 
loops that tolerate much sequence diversity, and dif-
ferent binding motifs could potentially be engineered 
into  these  loops  to  create bioactive  knottins  against 
different  molecular  targets  [51,  52].  Several  knottin 
mutants that bind to integrin receptors (αvβ3/αvβ5 or 
αvβ3/αvβ5/α5β1) with low nanomolar affinity have 
been identified [51, 52], and radionuclide and optical 
dye labeled such knottin peptides have demonstrated 
favorable in vivo tumor targeting properties [53-56]. 
Recently,  two  knottin  peptides  (2.5D  and  2.5F:  tar-
geting  integrin  αvβ3/αvβ5  and  αvβ3/αvβ5/α5β1, 
respectively)  were  radiolabeled  with  a  therapeutic 
radionuclide  177Lu,  and  the  resulting  radiopharma-
ceuticals were evaluated for potential radiotherapy in 
a mouse model of human glioma [57]. Compared to 
177Lu-DOTA-2.5D,  177Lu-DOTA-2.5F  showed  much 
higher  tumor  uptake  and  tumor  to  blood  ratios,  as 
well as a higher tumor to kidney radiation absorbed 
dose ratio, demonstrating the more promising appli-
cation of 177Lu-DOTA-2.5F as a targeted radionuclide 
therapeutic agents for integrin-positive tumors.  
Radionuclide therapy targeting other integ-
rins 
Although  integrin  αvβ3  has  been  extensively 
studied as one of the key players in tumor angiogen-
esis,  other  integrin  members  such  as  integrin  α2β1, 
α3β1,  α4β1,  αvβ5  and  αvβ6  are  involved  in  these 
processes as well. Comparing with integrin αvβ3, the 
literature reports of other integrins targeted molecular 
imaging and drug delivery are relatively rare.   
A high-affinity peptidomimetic ligand (LLP2A; 
IC50 = 2 pM) against α4β1 integrin was identified by 
using  both  diverse  and  highly  focused 
one-bead-one-compound  combinatorial  pep-
tidomimetic  libraries  in  conjunction  with 
high-stringency  screening  [58].  LLP2A  was  demon-Theranostics 2011, 1 
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strated  that  can  be  used  to  image  α4β1-expressing 
lymphomas with high sensitivity and specificity when 
conjugated  to  a  near  infrared  fluorescent  dye  in  a 
mouse  xenograft  model.  Thus,  LLP2A  shows  great 
potential  as  an  imaging  and  therapeutic  agent  for 
α4β1-positive tumors [58]. In the subsequent studies, 
the near infrared fluorescent dye Cy5.5, 64Cu and 111In 
labeled LLP2A was investigated for optical imaging, 
microPET and whole-body autoradiography (WBAR) 
of tumors, respectively [59, 60]. The s.c. tumors can be 
clearly visualized after i.v. injection of the conjugates, 
which  warrants  further  investigation  of  the  LLP2A 
conjugates as agents for α4β1 targeted imaging and 
therapy of human lymphoid malignancies. Unfortu-
nately,  to  date,  the  integrin  α4β1  targeted  radionu-
clide  therapy  for  tumors  in  preclinical  and  clinical 
investigations  have  not  been  reported.  A  peptide 
NAVPNLRGDLQVLAQKVART  (denoted  as 
A20FMDV2),  derived  from  foot-and-mouth  disease 
virus, has been identified as a potent inhibitor of αvβ6 
[61], which is low or undetectable in most adult tis-
sues but is up-regulated dramatically in many carci-
noma tumors [62]. A20FMDV2 was radiolabeled with 
18F and tested in mice bearing both αvβ6-negative and 
αvβ6-positive  tumor  xenografts  [63].  Rapid  uptake 
and  selective  retention  of  radioactivity  in  the 
αvβ6-positive  tumor,  together  with  the  fast  renal 
elimination  of  non-specifically  bound  activity,  re-
sulted  in  receptor  specific  imaging  of  the 
αvβ6-positive neoplasm with good contrast. To fur-
ther  improve  the  tumor  targeting  property  and  in-
crease  the  retention  in  the  target  tissue,  two 
PEGylated  A20FMDV2  variants  were  prepared  and 
both showed significantly improved retention in two 
αvβ6-expressing  human  tumor  xenograft  models, 
making  them  promising  for  molecular  imaging  of 
integrin αvβ6 expression [64]. However, for targeted 
radionuclide  therapy  of  tumors,  the  PEGylated 
A20FMDV2 tracers may have limitations due to the 
low tumor uptake values (less than 3 %ID/g). To de-
velop radiopharmaceuticals for α3β1 integrin target-
ing, an all D-amino acid analog of the residues 531-542 
from the α1 chain of type IV collagen (which binds to 
α3β1 integrin) was synthesized by solid-phase meth-
ods, and then labeled with  64Cu [65]. The tumor ac-
cumulation of the tracer was very low (< 2 %ID/g) 
and blocking studies failed to reduce the tumor up-
take,  confirming  that  the  low  tumor  uptake  was 
mostly non-specific accumulation. The combination of 
the results obtained from the in vitro and in vivo data 
strongly suggest that peptides of this class targeted to 
the  α3β1  would  not  be  suitable  as  in vivo  imaging 
agents in humans [65]. 
Radiotherapeutics  targeting  integrins  besides 
αvβ3 have not been well investigated may largely due 
to the lack of high affinity/specificity ligands to each 
integrin. Therefore, ligand screening strategies, such 
as phage display, may play a major role in identifying 
novel ligands for each integrin. The optimizing strat-
egies, such as multivalency [33] and PEGylation [66], 
may  also  be  involved  in  the  development  of  opti-
mized ligands, which may open up new perspectives 
for cancer therapy based on integrin targeted radio-
therapeutics. 
Conclusions  
Integrins are the key regulators of tumor angio-
genesis and metastasis. The vast number of literature 
reports  on  anti-angiogenic  cancer  therapy  based  on 
integrin antagonism confirmed the validity of integrin 
αvβ3 as an anti-cancer target. However, the investi-
gation  of  integrin  αvβ3  targeted  delivery  of  radio-
therapeutics is relatively rare. Integrin targeted radi-
onuclide therapy is considered to specifically deliver 
radiation  to  the  tumor  cells  or  tumor  vasculature, 
thereafter leading to the death of tumor cells and the 
inhibition  of  tumor  growth.  Integrin  αvβ3  targeted 
RIT with 90Y-labeled humanized antibody AbegrinTM 
was  investigated  in  human  glioblastoma  xenografts 
and  it  was  demonstrated  the  promising  results  for 
anti-tumor therapy. However, the radiation uptake in 
normal organs especially in the liver and spleen was 
high due to the slow circulation clearance and liver 
excretion  of the intact antibody.  RGD peptides that 
specifically targeting integrin αvβ3 were also inves-
tigated for radionuclide therapy of tumors with rapid 
blood  clearance  and  optimized  tumor  penetration. 
However, the tumor inhibition efficacies of RGD pep-
tides-based radiotherapeutics were nonoptimized due 
to the lower tumor uptake. Therefore, further research 
effort is still needed to develop novel integrin targeted 
radiotherapeutics with better tumor targeting efficacy 
and  desirable  pharmacokinetics.  In  addition,  the 
combination  of  integrin  targeted  radiation  therapy 
with  other  therapeutic  modalities,  such  as  chemo-
therapy,  is  also  expected  to  generate  significantly 
greater anti-tumor benefits.  
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